{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:19:43Z","timestamp":1781932783380,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310113"],"award-info":[{"award-number":["JP19fk0310113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19am0101071"],"award-info":[{"award-number":["JP19am0101071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310113"],"award-info":[{"award-number":["JP19fk0310113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0410015"],"award-info":[{"award-number":["JP19fk0410015"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310113"],"award-info":[{"award-number":["JP19fk0310113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis B virus (HBV) infection is a major public health problem that affects millions of people worldwide. Nucleoside analogue reverse transcriptase (RT) inhibitors, such as entecavir (ETV) and lamivudine (3TC), serve as crucial anti-HBV drugs. However, structural studies of HBV RT have been hampered due to its unexpectedly poor solubility. Here, we show that human immunodeficiency virus type-1 (HIV-1) with HBV-associated amino acid substitutions Y115F\/F116Y\/Q151M in its RT (HIV<jats:sup>Y115F\/F116Y\/Q151M<\/jats:sup>) is highly susceptible to ETV and 3TC. Additionally, we experimentally simulated previously reported ETV\/3TC resistance for HBV using HIV<jats:sup>Y115F\/F116Y\/Q151M<\/jats:sup> with F160M\/M184V (L180M\/M204V in HBV RT) substituted. We determined crystal structures for HIV-1 RT<jats:sup>Y115F\/F116Y\/Q151M<\/jats:sup>:DNA complexed with 3TC-triphosphate (3TC-TP)\/ETV-triphosphate (ETV-TP)\/dCTP\/dGTP. These structures revealed an atypically tight binding conformation of 3TC-TP, where the Met184 side-chain is pushed away by the oxathiolane of 3TC-TP and exocyclic methylene of ETV-TP. Structural analysis of RT<jats:sup>Y115F\/F116Y\/Q151M\/F160M\/M184V<\/jats:sup>:DNA:3TC-TP also demonstrated that the loosely bound 3TC-TP is misaligned at the active site to prevent a steric clash with the side chain \u03b3-methyl of Val184. These findings shed light on the common structural mechanism of HBV and HIV-1 resistance to 3TC and ETV and should aid in the design of new agents to overcome drug resistance to 3TC and ETV.<\/jats:p>","DOI":"10.1038\/s41598-020-59775-w","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:03:11Z","timestamp":1582196591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-7516","authenticated-orcid":false,"given":"Yoshiaki","family":"Yasutake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kohgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-1491","authenticated-orcid":false,"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"59775_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/epirev\/mxj009","volume":"28","author":"CW Shepard","year":"2006","unstructured":"Shepard, C. W., Simard, E. P., Finelli, L., Fiore, A. E. & Bell, B. P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28, 112\u2013125 (2006).","journal-title":"Epidemiol. Rev."},{"key":"59775_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. 11, 97\u2013107 (2004).","journal-title":"J. Viral. Hepat."},{"key":"59775_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","volume":"29","author":"J Summers","year":"1982","unstructured":"Summers, J. & Mason, W. S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29, 403\u2013415 (1982).","journal-title":"Cell"},{"key":"59775_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","volume":"64","author":"C Seeger","year":"2000","unstructured":"Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64, 51\u201368 (2000).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"59775_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/JVI.68.1.6-13.1994","volume":"68","author":"F Zoulim","year":"1994","unstructured":"Zoulim, F. & Seeger, C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68, 6\u201313 (1994).","journal-title":"J. Virol."},{"key":"59775_CR6","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1128\/JVI.68.5.2994-2999.1994","volume":"68","author":"M Weber","year":"1994","unstructured":"Weber, M. et al. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J. Virol. 68, 2994\u20132999 (1994).","journal-title":"J. Virol."},{"key":"59775_CR7","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1128\/JVI.02575-13","volume":"88","author":"J V\u00f6r\u00f6s","year":"2013","unstructured":"V\u00f6r\u00f6s, J. et al. Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase. J. Virol. 88, 2584\u20132599 (2013).","journal-title":"J. Virol."},{"key":"59775_CR8","doi-asserted-by":"publisher","first-page":"11329","DOI":"10.1073\/pnas.1321424111","volume":"111","author":"JC-Y Wang","year":"2014","unstructured":"Wang, J. C.-Y., Nickens, D. G., Lentz, T. B., Loeb, D. D. & Zlotnick, A. Encapsidated hepatitis B virus reverse transcriptase is poised on an ordered RNA lattice. Proc. Natl. Acad. Sci. USA 111, 11329\u201311334 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59775_CR9","doi-asserted-by":"publisher","first-page":"9274","DOI":"10.1073\/pnas.1605223113","volume":"113","author":"ZL Salie","year":"2016","unstructured":"Salie, Z. L. et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA). Proc. Natl. Acad. Sci. USA 113, 9274\u20139279 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59775_CR10","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1093\/emboj\/cdf637","volume":"21","author":"SG Sarafianos","year":"2002","unstructured":"Sarafianos, S. G. et al. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21, 6614\u20136624 (2002).","journal-title":"EMBO J."},{"key":"59775_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/nsmb.1908","volume":"17","author":"X Tu","year":"2010","unstructured":"Tu, X. et al. Structural basis of HIV-1 resistance to AZT by excision. Nat. Struct. Mol. Biol. 17, 1202\u20131209 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"59775_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb760","volume":"11","author":"S Tuske","year":"2004","unstructured":"Tuske, S. et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11, 469\u2013474 (2004).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"59775_CR13","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.1073\/pnas.1814170116","volume":"116","author":"K Das","year":"2019","unstructured":"Das, K., Martinez, S. E., DeStefano, J. J. & Arnold, E. Structure of HIV-1 RT\/dsRNA initiation complex prior to nucleotide incorporation. Proc. Natl. Acad. Sci. USA 116, 7308\u20137313 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59775_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/17460794.4.1.55","volume":"4","author":"M Nassal","year":"2009","unstructured":"Nassal, M. New insights into HBV replication: new opportunities for improved therapies. Future Virol. 4, 55\u201370 (2009).","journal-title":"Future Virol."},{"key":"59775_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem. Pharmacol. 119, 1\u20137 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"59775_CR16","first-page":"59","volume":"18","author":"JL Casado","year":"2016","unstructured":"Casado, J. L. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 18, 59\u201368 (2016).","journal-title":"AIDS Rev."},{"key":"59775_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","volume":"63","author":"S Hayashi","year":"2015","unstructured":"Hayashi, S. et al. Characterization of novel entecavir resistance mutations. J. Hepatol. 63, 546\u2013553 (2015).","journal-title":"J. Hepatol."},{"key":"59775_CR18","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1128\/AAC.46.8.2525-2532.2002","volume":"46","author":"S Levine","year":"2002","unstructured":"Levine, S. et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46, 2525\u20132532 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"59775_CR19","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1056\/NEJMoa067710","volume":"356","author":"MA McMahon","year":"2007","unstructured":"McMahon, M. A. et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N. Engl. J. Med. 356, 2614\u20132621 (2007).","journal-title":"N. Engl. J. Med."},{"key":"59775_CR20","doi-asserted-by":"publisher","first-page":"10027","DOI":"10.1073\/pnas.96.18.10027","volume":"96","author":"SG Sarafianos","year":"1999","unstructured":"Sarafianos, S. G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA 96, 10027\u201310032 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59775_CR21","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1039\/C4MB00253A","volume":"10","author":"S Bhakat","year":"2014","unstructured":"Bhakat, S., Martin, A. J. & Soliman, M. E. An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine. Mol. Biosyst. 10, 2215\u20132228 (2014).","journal-title":"Mol. Biosyst."},{"key":"59775_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/095632020301400603","volume":"14","author":"Y Chong","year":"2003","unstructured":"Chong, Y., Stuyver, L., Otto, M. J., Schinazi, R. F. & Chu, C. K. Mechanism of antiviral activities of 3\u2032-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach. Antivir. Chem. Chemother. 14, 309\u2013319 (2003).","journal-title":"Antivir. Chem. Chemother."},{"key":"59775_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1006\/jmbi.2000.3823","volume":"300","author":"HQ Gao","year":"2000","unstructured":"Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E. & Hughes, S. H. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 300, 403\u2013418 (2000).","journal-title":"J. Mol. Biol."},{"key":"59775_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19602-9","volume":"8","author":"Y Yasutake","year":"2018","unstructured":"Yasutake, Y. et al. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir. Sci. Rep. 8, 1624 (2018).","journal-title":"Sci. Rep."},{"key":"59775_CR25","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1128\/JVI.02395-06","volume":"81","author":"DR Langley","year":"2007","unstructured":"Langley, D. R. et al. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 81, 3992\u20134001 (2007).","journal-title":"J. Virol."},{"key":"59775_CR26","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1128\/JVI.70.8.5642-5645.1996","volume":"70","author":"Y Quan","year":"1996","unstructured":"Quan, Y. et al. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (\u2212)2\u2032-dideoxy-3\u2032-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70, 5642\u20135645 (1996).","journal-title":"J. Virol."},{"key":"59775_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/infdis\/169.4.722","volume":"169","author":"RW Shafer","year":"1994","unstructured":"Shafer, R. W. et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169, 722\u2013729 (1994).","journal-title":"J. Infect. Dis."},{"key":"59775_CR28","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1073\/pnas.92.6.2398","volume":"92","author":"T Shirasaka","year":"1995","unstructured":"Shirasaka, T. et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92, 2398\u20132402 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59775_CR29","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/AAC.00277-07","volume":"51","author":"H Nakata","year":"2007","unstructured":"Nakata, H. et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine. Antimicrob. Agents Chemother. 51, 2701\u20132708 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"59775_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/hep.27962","volume":"62","author":"Y Takamatsu","year":"2015","unstructured":"Takamatsu, Y. et al. 4\u2032-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology 62, 1024\u20131036 (2015).","journal-title":"Hepatology"},{"key":"59775_CR31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.chembiol.2018.07.014","volume":"25","author":"Y Takamatsu","year":"2018","unstructured":"Takamatsu, Y. et al. The high genetic barrier of 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA\/MK-8591) stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase. Cell Chem. Biol. 25, 1268\u20131278.e3 (2018).","journal-title":"Cell Chem. Biol."},{"key":"59775_CR32","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.bbrc.2019.01.026","volume":"509","author":"Y Yasutake","year":"2019","unstructured":"Yasutake, Y. et al. Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4\u2032-modified nucleoside RT inhibitors. Biochem. Biophys. Res. Commun. 509, 943\u2013948 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"59775_CR33","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-017-0754-9","volume":"77","author":"LJ Scott","year":"2016","unstructured":"Scott, L. J. & Chan, H. L. Y. Tenofovir alafenamide: a review in chronic hepatitis B. Drugs 77, 1017\u20131028 (2016).","journal-title":"Drugs"},{"key":"59775_CR34","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/pro.3681","volume":"28","author":"N Bertoletti","year":"2019","unstructured":"Bertoletti, N., Chan, A. H., Schinazi, R. F., Yin, Y. W. & Anderson, K. S. Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Sci. 28, 1664\u20131675 (2019).","journal-title":"Protein Sci."},{"key":"59775_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1128\/AAC.01229-10","volume":"55","author":"JA Brown","year":"2011","unstructured":"Brown, J. A., Pack, L. R., Fowler, J. D. & Suo, Z. Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases. Antimicrob. Agents Chemother. 55, 276\u2013283 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"59775_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/bi982340r","volume":"38","author":"JY Feng","year":"1999","unstructured":"Feng, J. Y. & Anderson, K. S. Mechanistic studies comparing the incorporation of (+) and (\u2212) isomers of 3TCTP by HIV\u20101 reverse transcriptase. Biochem. 38, 55\u201363 (1999).","journal-title":"Biochem."},{"key":"59775_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/mutage\/gei019","volume":"20","author":"OA Olivero","year":"2005","unstructured":"Olivero, O. A. et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 20, 139\u2013146 (2005).","journal-title":"Mutagenesis"},{"key":"59775_CR38","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1073\/pnas.92.7.2760","volume":"92","author":"Z Gu","year":"1995","unstructured":"Gu, Z., Arts, E. J., Parniak, M. A. & Wainberg, M. A. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2\u2032,3\u2032-dideoxycytidine 5\u2032-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92, 2760\u20132764 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59775_CR39","doi-asserted-by":"publisher","first-page":"35092","DOI":"10.1074\/jbc.M109.022525","volume":"284","author":"K Das","year":"2009","unstructured":"Das, K. et al. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J. Biol. Chem. 284, 35092\u201335100 (2009).","journal-title":"J. Biol. Chem."},{"key":"59775_CR40","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1128\/JVI.80.10.4971-4977.2006","volume":"80","author":"UM Parikh","year":"2006","unstructured":"Parikh, U. M., Bacheler, L., Koontz, D. & Mellors, J. W. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80, 4971\u20134977 (2006).","journal-title":"J. Virol."},{"key":"59775_CR41","doi-asserted-by":"publisher","first-page":"pii: e02143","DOI":"10.1128\/AAC.02143-18","volume":"63","author":"N Higashi-Kuwata","year":"2019","unstructured":"Higashi-Kuwata, N. et al. CMCdG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus. Antimicrob. Agents Chemother. 63, pii: e02143\u201318 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"59775_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","volume":"156","author":"Y Xia","year":"2019","unstructured":"Xia, Y. & Liang, T. Development of Direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus Infection. Gastroenterology 156, 311\u2013324 (2019).","journal-title":"Gastroenterology"},{"key":"59775_CR43","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1107\/S2053230X15017896","volume":"71","author":"A Nakamura","year":"2015","unstructured":"Nakamura, A., Tamura, N. & Yasutake, Y. Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase. Acta Crystallogr. Sect. F. 71, 1384\u20131390 (2015).","journal-title":"Acta Crystallogr. Sect. F."},{"key":"59775_CR44","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.1093\/nar\/17.16.6545","volume":"17","author":"A Hemsley","year":"1989","unstructured":"Hemsley, A., Arnheim, N., Toney, M. D., Cortopassi, G. & Galas, D. J. A simple method for site-directed mutagenesis using the polymerase chain reaction. Nucleic Acids Res. 17, 6545\u20136551 (1989).","journal-title":"Nucleic Acids Res."},{"key":"59775_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3851\/IMP2697","volume":"19","author":"K Maeda","year":"2014","unstructured":"Maeda, K. et al. Delayed emergence of HIV-1 variants resistant to 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir. Ther. 19, 179\u2013189 (2014).","journal-title":"Antivir. Ther."},{"key":"59775_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/nar\/gkj426","volume":"34","author":"JJ DeStefano","year":"2006","unstructured":"DeStefano, J. J. & Cristofaro, J. V. Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res. 34, 130\u2013139 (2006).","journal-title":"Nucleic Acids Res."},{"issue":"46\u201355","key":"59775_CR47","first-page":"2015","volume":"25","author":"MT Miller","year":"2015","unstructured":"Miller, M. T., Tuske, S., Das, K., DeStefano, J. J. & Arnold, E. Structure of HIV-1 reverse transcriptase bound to a novel 38-mer hairpin template-primer DNA aptamer. Protein Sci. 25(46\u201355), 2015 (2015).","journal-title":"Protein Sci."},{"key":"59775_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"59775_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1107\/S0907444905036693","volume":"62","author":"P Evans","year":"2006","unstructured":"Evans, P. Scaling and assessment of data quality. Acta Crystallogr. Sect. D. 62, 72\u201382 (2006).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"59775_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D. 67, 355\u2013367 (2011).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"59775_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D. 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"59775_CR52","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"59775_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. Phenix: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"59775_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. Sect. D."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59775-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59775-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59775-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:18:44Z","timestamp":1670311124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59775-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["59775"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-59775-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"10 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3021"}}